Open AccessRandomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
Author(s) -
Jonathan E. Rosenberg,
Karla V. Ballman,
Susan Halabi,
Pamela J. Atherton,
Amir Mortazavi,
Christopher J. Sweeney,
Walter M. Stadler,
Benjamin A. Teply,
Joel Picus,
Scott T. Tagawa,
Sreedhar Katragadda,
Daniel A. Vaena,
Jamal Misleh,
Christopher J. Hoimes,
Elizabeth R. Plimack,
Thomas W. Flaig,
Robert Dreicer,
Dean F. Bajorin,
Olwen Hahn,
Eric J. Small,
Michael J. Morris
Publication year - 2021
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.00286
Subject(s) - medicine , bevacizumab , hazard ratio , gemcitabine , clinical endpoint , placebo , oncology , metastatic urothelial carcinoma , chemotherapy , progression free survival , surgery , randomized controlled trial , urology , cancer , urothelial carcinoma , bladder cancer , pathology , confidence interval , alternative medicine
The combination of gemcitabine and cisplatin (GC) is a standard therapy for metastatic urothelial carcinoma. Based on data that angiogenesis plays a role in urothelial carcinoma growth and progression, a randomized placebo-controlled trial was performed with the primary objective of testing whether patients treated with GC and bevacizumab (GCB) have superior overall survival (OS) than patients treated with GC and placebo (GCP).